CDK2 and colorectal carcinoma: The human cyclin-dependent kinase 2 (CDK2) has also been observed to be overexpressed in CRC patients, thus, inhibition and/or downregulation of this kinase has also emerged as a strategy for tackling CRC [9, 10].